Title:
PHARMACEUTICAL COMPOSITION CONTAINING PRION PROTEIN-SPECIFIC ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2021/125477
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for treating cancer containing prion protein-specific antibody.
Inventors:
LEE SANG HUN (KR)
YUN CHUL WON (KR)
YUN CHUL WON (KR)
Application Number:
PCT/KR2020/008912
Publication Date:
June 24, 2021
Filing Date:
July 08, 2020
Export Citation:
Assignee:
STEM BIO CO LTD (KR)
LEE SANG HUN (KR)
LEE SANG HUN (KR)
International Classes:
A61K39/395; A61K31/513; A61K31/555; A61K39/00; A61K47/68; A61P35/00; C07K16/28
Foreign References:
| US20140308272A1 | 2014-10-16 | |||
| KR20190037012A | 2019-04-05 | |||
| JP2012519190A | 2012-08-23 |
Other References:
MCEWAN J F; WINDSOR M L; CULLIS-HILL S D: "Antibodies to prion protein inhibit human colon cancer cell growth", TUMOR BIOLOGY, vol. 30, no. 3, 1 August 2009 (2009-08-01), pages 141 - 147, XP009135008, ISSN: 1010-4283, DOI: 10.1159/000225243
JUN HEE LEE, CHUL WON YUN, SANG HUN LEE: "Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway", BIOMOLECULES & THERAPEUTICS, vol. 26, no. 3, 1 May 2018 (2018-05-01), pages 313 - 321, XP055823168, ISSN: 2005-4483, DOI: 10.4062/biomolther.2017.033
JUN HEE LEE, CHUL WON YUN, SANG HUN LEE: "Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway", BIOMOLECULES & THERAPEUTICS, vol. 26, no. 3, 1 May 2018 (2018-05-01), pages 313 - 321, XP055823168, ISSN: 2005-4483, DOI: 10.4062/biomolther.2017.033
Attorney, Agent or Firm:
HAN, Sang Soo (KR)
Download PDF: